{
  "type": "analysis_section_rewrite",
  "timestamp": "2025-08-24T12:19:31",
  "processed": false,
  "inputs": {
    "topic_id": "fed_policy",
    "section": "medium",
    "test": "False",
    "run_id": "fed_policy__analysis_run__1756030660",
    "article_ids": "['SK994CBWR', 'Q7VVGNSQE', 'C22MKA9VY', 'SK994CBWR', 'Q7VVGNSQE']",
    "selected_articles_count": "5",
    "material_chars": "98831",
    "output_chars": "4111",
    "saved": "True",
    "saved_field": "medium_analysis",
    "status": "success"
  },
  "details": {
    "llm": {
      "model": "gpt-5-nano",
      "feedback": "Actionable edit plan to elevate to world‑class in 3–6 months: 1) tighten the causal chain from macro/policy to ACMR’s stock trajectory by explicitly tying the Q2 print (revenue $215m, net income $30m, gross margin 49.4%, debt ~23%) and the Ultra C wb N2 bubbling upgrade to the 2025 guidance ($850–$950m) and to potential multiple re‑rating under a softer rate regime, clearly naming SK994CBWR as the data backbone and noting the 2028 consensus revenue path ($1.4b) as a horizon read‑through; 2) construct a formal scenario map with timing windows: Base (3–6 months) assumes rate cuts totaling ~150bp starting Sep (first 50bp in Sep, per C22MKA9VY) and a small‑cap rotation that could lift ACMR toward mid‑to‑high $30s (target $34–$36; use consensus $34.76 as a benchmark); Alt 1 assumes rate cuts disappoint or export controls tighten, keeping ACMR in $30–$32; Alt 2 assumes IPO momentum/improving small‑cap fundamentals accelerates, pushing toward the upper end of the range; define triggers and invalidations for each (e.g., actual rate cuts and Fed guidance; IPO cadence/quality signals; clear progress or setback in U.S.–China tech flows); 3) strengthen first‑principles framing by clearly delineating ACMR’s earnings power drivers (High gross margin ~49%, EPS $1.75 TTM, strong cash generation cited in SK994CBWR) and how a lower discount rate would compress WACC/EV multiples for a growth hardware/software‑enabled model; 4) sharpen quantification with precise numbers: anchor base/alt targets, probability weights, and sensitivity to rate path (e.g., ±50bp in either direction); 5) reconcile conflicts by candidly presenting both viewpoints from sources: Russell 2000 small‑cap regime thesis (Q7VVGNSQE) alongside ACMR’s idiosyncratic risks (U.S.–China tensions, export controls from SK994CBWR), and show how they interact under each scenario; 6) tighten formatting to meet horizon focus—end with a base case, 1–2 alts, a risks section, watch‑list signals, and a succinct confidence statement; 7) ensure every factual claim tied to ACMR data cites SK994CBWR and every macro/IPO/policy claim cites C22MKA9VY or Q7VVGNSQE as appropriate, with direct linkage to their numeric specifics (e.g., 95 IPOs in 2025, $12.9b raised; consensus target $34.76; 52‑week band $13.87–$32.54).",
      "tokens": {}
    }
  },
  "id": "fed_policy__medium__fed_policy__analysis_run__1756030660"
}